latest update:
[TrialBase DB]

trial summary · NCT07556484

Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

Pharmacokinetics Of Emulsified Avacopan In ANCA-associated Vasculitis With Severe Diffuse Alveolar Hemorrhage

Trial record from the TrialBase DB dataset, status RECRUITING, condition Diffuse Alveolar Hemorrhage, sponsored by Mayo Clinic. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07556484phase PHASE1enrollment 6start 2027-08-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with active severe GPA or MPA with diffuse alveolar hemorrhage (DAH) requiring mechanical ventilation for respiratory support.

Source record: https://clinicaltrials.gov/study/NCT07556484

Facts

registry idNCT07556484
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionDiffuse Alveolar Hemorrhage
sponsorMayo Clinic
sponsor classOTHER
enrollment6
start date2027-08-01
primary completion2028-08-01
completion2028-08-01
results postednot reported

Conditions

  • Diffuse Alveolar Hemorrhage
  • Antineutrophil Cytoplasmic Antibody Positive Vasculitis

Interventions

  • Avacopan

Countries

  • United States

Intervention types: DRUG

Work with this record